Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
March 20, 2026 16:30 ET | Source: Zevra Therapeutics BOSTON, March 20,…
Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics
The Atlas will expand known evolutionary genetic diversity by 100x, collecting novel…
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
March 17, 2026 22:46 ET | Source: CytomX Therapeutics Inc. SOUTH SAN…
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026 17:33 ET | Source: Tango Therapeutics Sub, Inc BOSTON,…
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
March 06, 2026 18:15 ET | Source: Lisata Therapeutics, Inc. Each Lisata…
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Presented positive updated data from the ALLOHA™ Phase 1 heme trial at…
Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Phase 1b/2a Agent and Announces First Close of Seed Financing
Chesterbrook, PA, March 03, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc. (“Persevere”),…
Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit
LEHI, Utah, March 2, 2026 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical…
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated…
Polaroid Therapeutics (PTx) Receives CE Mark for POLTX_Fiber: the first application of APT to launch a new standard in wound care
Introducing Antimicrobial Polymer Technology (APT™) in POLTX_Fiber™, a Class IIb advanced wound…
